Synergistic anti-tumour effect of doxorubicin-hydrochloride with CRM197, an inhibitor of HB-EGF, in squamous-cell carcinoma

Simple item page
dc.contributor.authorRadevych, І.en_US
dc.contributor.authorSiromolot, Andriyen_US
dc.contributor.authorKolybo, Denysen_US
dc.date.accessioned2025-03-11T06:59:22Z
dc.date.available2025-03-11T06:59:22Z
dc.date.issued2024
dc.description.abstractСancer is one of the greatest threats to public health, its lethality comparable only to that of cardiovascular diseases, with the approach to its prevention and therapy evolving from populationbased and epidemiological studies to targeted delivery and immunological approaches. Recent studies have shown that cross reacting material (CRM197), a nontoxic variant of diphtheria toxin may play an important role in treating cancers with poor prognoses by inhibiting heparin-binding EGF-like growth factor (HB-EGF) [1, 2]. Doxorubicin-hydrochloride (DOX) is an antineoplastic prescription medicine approved by the U.S. Food and Drug Administration for the treatment of certain types of cancer, including ovarian cancer and multiple myeloma [3]. Considering that CRM197 is a known carrier in targeted delivery, CRM197-DOX complexes might be a step towards targeted therapy and reduced overall toxicity.en_US
dc.identifier.citationRadevych, І. І. Synergistic anti-tumour effect of doxorubicin-hydrochloride with CRM197, an inhibitor of HB-EGF, in squamous-cell carcinoma / I. I. Radevych, A. A. Siromolot, D. V. Kolybo // Biotechnologia Acta. - 2024. - Vol. 17, No 2. - Р. 64-66. - https://doi.org/10.15407/biotech17.02.064en_US
dc.identifier.issn2410-7751
dc.identifier.issn2410-776X
dc.identifier.urihttps://doi.org/10.15407/biotech17.02.064
dc.identifier.urihttps://ekmair.ukma.edu.ua/handle/123456789/33877
dc.language.isoenen_US
dc.relation.sourceBiotechnologia Actaen_US
dc.statusfirst publisheden_US
dc.subjectCRM197en_US
dc.subjectdoxorubicinen_US
dc.subjectepidermoid carcinomaen_US
dc.subjecttargeted treatmenten_US
dc.subjectconference materialsen_US
dc.titleSynergistic anti-tumour effect of doxorubicin-hydrochloride with CRM197, an inhibitor of HB-EGF, in squamous-cell carcinomaen_US
dc.typeConference materialsen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Radevych_Synergistic_anti_tumour_effect_of_doxorubicin_hydrochloride_with_CRM197_an_inhibitor_of_HB_EGF_in_squamous_cell_carcinoma.pdf
Size:
138.28 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Кафедра лабораторної діагностики біологічних систем